TLDR
- Moderna stock posted a 30% gain in the first eight sessions of 2026, topping the S&P 500
- The company raised 2025 revenue expectations to about $1.9 billion and announced operating expense reductions
- A bullish golden cross pattern emerged with the 50-day moving average crossing above the 200-day line
- Technical analysts project the stock could reach $64 by year end following breakout above $36
- Projected annual revenue growth of 10% driven by vaccine agreements, product launches, and trial outcomes
Moderna is off to a flying start in 2026. The stock has soared 30% in just the first eight trading days of the year. That makes it the strongest performer in the entire S&P 500 index.
What sparked the move? The company updated its financial outlook. Moderna increased its 2025 revenue projection to around $1.9 billion. It also revealed plans to cut operating expenses. Investors liked what they heard.
Shares traded at $38.50 on Tuesday after pushing past the $36 mark. That level has become important for traders watching the stock’s next move.
The technical picture is turning heads. A golden cross appeared recently when the 50-day moving average moved above the 200-day moving average. Chart watchers view this as a bullish signal that confirms changing momentum.
Since early December, the stock has stayed close to its 21-day exponential moving average. This behavior is typical of stocks in an uptrend. It shows buyers are active and defending price dips.
Pattern Recognition Points Higher
A double bottom formation with a handle is developing on the charts. Technical strategists believe this pattern could push shares toward $64 before 2026 ends. That would mark a solid advance from current trading levels.
The recommendation to buy at $30 in late 2025 has paid off. The stock has added nearly 30% since that call.
The biotech sector overall has been recovering. The SPDR S&P Biotech ETF hit bottom at $66.66 last April and has rallied more than 90% since. The fund has climbed in 29 of the last 40 weeks.
Moderna is beating its sector peers. When compared directly to the biotech ETF, the stock shows clear relative strength. This outperformance began in December and has continued into the new year.
Growth Outlook and Pipeline Progress
Revenue is expected to grow at approximately 10% per year. That growth comes from multiple sources. Vaccine contracts provide steady income. New product approvals will add to the top line.
The company has drugs in late-stage testing. Programs in oncology and rare diseases are advancing through trials. Success in these areas would strengthen the business case.
Management set a goal to achieve breakeven by 2028. For a company still recording losses, this target matters. Shareholders will monitor progress toward profitability.
The market cap stands at $13.4 billion. Daily trading volume averages 10.8 million shares. The stock is up 14.75% year to date.
Some concerns remain. The company hasn’t turned profitable yet. Insider selling has occurred recently. Price volatility can be sharp at times.
Tuesday’s trading suggested institutions are buying. Large-scale accumulation often indicates professional investors see value. That type of activity can support prices.
After spending 2025 building a base, the stock appears to be shifting gears. The early 2026 price action backs up this view. Momentum has clearly swung positive.
Support levels are holding firm. Resistance zones are giving way. For traders who follow trends, the setup looks attractive right now.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
